# A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Study · id `cardio:ct-nct02012075` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02012075](<https://clinicaltrials.gov/study/NCT02012075>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02012075

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 316 participants.

## Technical summary

Registry record NCT02012075. Randomized; double masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 316 participants (planned count; ClinicalTrials.gov record NCT02012075, source copy `cardio:ctgov-nct02012075-2013-12-16`, retrieved 2026-10-26)
- Start date: 2013-12 (registry gives no type) (ClinicalTrials.gov record NCT02012075, source copy `cardio:ctgov-nct02012075-2013-12-16`, retrieved 2026-10-26)
- Primary completion: 2015-02 (anticipated) (ClinicalTrials.gov record NCT02012075, source copy `cardio:ctgov-nct02012075-2013-12-16`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: China (ClinicalTrials.gov record NCT02012075, source copy `cardio:ctgov-nct02012075-2013-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02012075-2013-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
- Condition: Heart Failure
- Intervention (Drug): Extended-Release Carvedilol Sulfate
- Intervention (Drug): Sustained-release Metoprolol Succinate
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 1cdb431ba0e67faeeab55c46eac70587535eae00d6e185cf59feaa580651f517
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
